Compile Data Set for Download or QSAR
Report error Found 55 Enz. Inhib. hit(s) with all data for entry = 986
TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM301799(US9598370, Example 00133 | USRE47437, Example {[5-...)
Affinity DataEC50:  4.30E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107711(US8722895, 17: 5-(3-Chlorophenyl)-N-(2-methylamino...)
Affinity DataEC50:  1.40E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107710(US8722895, 16: {[5-(2-Methyl-5-chlorophenyl)-3- hy...)
Affinity DataEC50:  3.30E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM301819(US9598370, Example 00143 | USRE47437, Example {[5-...)
Affinity DataEC50: >1.00E+5nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107709(US8722895, 15: {[5-(4-Isopropoxyphenyl)-3- hydroxy...)
Affinity DataEC50: >1.00E+5nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107708(US8722895, 14: {[5-(4-Chlorophenyl)-3-hydroxypyrid...)
Affinity DataEC50: >1.00E+5nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107707(US8722895, 13: {[5-(4-Isopropylphenyl)-3-hydroxypy...)
Affinity DataEC50:  1.50E+4nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US8598210, Table XV, 11 | US8598210, 119 | US87228...)
Affinity DataEC50:  7.60E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107701(US8722895, 7: {[5-(2-Chloro-phenyl)-3-hydroxy-pyri...)
Affinity DataEC50:  7.70E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107717(US8722895, 23: ({3-Hydroxy-5-[3-(pyrrolidine-1- ca...)
Affinity DataEC50: >1.00E+5nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM301820(US9598370, Example 00144 | USRE47437, Example ({3-...)
Affinity DataEC50: >1.00E+5nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107700(US8722895, 6: [(3-Hydroxy-5-(4-methylphenyl)-pyrid...)
Affinity DataEC50:  8.20E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107715(US8722895, 21: {[5-(3-Carbamoyl-phenyl)-3-hydroxy-...)
Affinity DataEC50:  5.01E+4nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107699(US8722895, 5: [(3-Hydroxy-4'-methyl-biphenyl-4...)
Affinity DataEC50: >1.00E+5nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM301825(US9598370, Example 00149 | USRE47437, Example ({3-...)
Affinity DataEC50: >1.00E+5nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107698(US8722895, 4: [(3-Hydroxy-5-(4-methylphenyl)pyridi...)
Affinity DataEC50:  4.21E+4nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107695(US8722895, 1: {[5-(3-chloro-phenyl)-3-hydroxy-pyri...)
Affinity DataEC50:  9.90E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107716(US8722895, 22: ({3-Hydroxy-5-[3-(pyrrolidine-1-car...)
Affinity DataEC50: >1.00E+5nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107696(US8722895, 2: {[5-(4-Chloro-phenyl)-3-hydroxy-pyri...)
Affinity DataEC50: >1.00E+5nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107714(US8722895, 20: {[5-(3-Cyanophenyl)-3-hydroxypyridi...)
Affinity DataEC50: >1.00E+5nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetVascular endothelial growth factor A(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM301787(US9598370, Example 00128 | USRE47437, Example {[5-...)
Affinity DataEC50: >1.00E+5nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107703(US8722895, 9: {[5-(4-Chlorophenyl)-3-hydroxypyridi...)
Affinity DataIC50: 83nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107698(US8722895, 4: [(3-Hydroxy-5-(4-methylphenyl)pyridi...)
Affinity DataIC50: 180nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107714(US8722895, 20: {[5-(3-Cyanophenyl)-3-hydroxypyridi...)
Affinity DataIC50: 190nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107703(US8722895, 9: {[5-(4-Chlorophenyl)-3-hydroxypyridi...)
Affinity DataIC50: 240nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107717(US8722895, 23: ({3-Hydroxy-5-[3-(pyrrolidine-1- ca...)
Affinity DataIC50: 300nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107708(US8722895, 14: {[5-(4-Chlorophenyl)-3-hydroxypyrid...)
Affinity DataIC50: 300nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US8598210, Table XV, 11 | US8598210, 119 | US87228...)
Affinity DataIC50: 390nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107706(US8722895, 12: {[5-(2-Chlorophenyl)-3-hydroxypyrid...)
Affinity DataIC50: 390nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM301825(US9598370, Example 00149 | USRE47437, Example ({3-...)
Affinity DataIC50: 400nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US8598210, Table XV, 11 | US8598210, 119 | US87228...)
Affinity DataIC50: 410nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107707(US8722895, 13: {[5-(4-Isopropylphenyl)-3-hydroxypy...)
Affinity DataIC50: 440nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM301799(US9598370, Example 00133 | USRE47437, Example {[5-...)
Affinity DataIC50: 560nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107698(US8722895, 4: [(3-Hydroxy-5-(4-methylphenyl)pyridi...)
Affinity DataIC50: 650nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107706(US8722895, 12: {[5-(2-Chlorophenyl)-3-hydroxypyrid...)
Affinity DataIC50: 1.10E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US8598210, Table XV, 11 | US8598210, 119 | US87228...)
Affinity DataIC50: 1.10E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107711(US8722895, 17: 5-(3-Chlorophenyl)-N-(2-methylamino...)
Affinity DataIC50: 1.20E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107711(US8722895, 17: 5-(3-Chlorophenyl)-N-(2-methylamino...)
Affinity DataIC50: 1.30E+3nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107709(US8722895, 15: {[5-(4-Isopropoxyphenyl)-3- hydroxy...)
Affinity DataIC50: 1.60E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107716(US8722895, 22: ({3-Hydroxy-5-[3-(pyrrolidine-1-car...)
Affinity DataIC50: 2.50E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107710(US8722895, 16: {[5-(2-Methyl-5-chlorophenyl)-3- hy...)
Affinity DataIC50: 2.50E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM301820(US9598370, Example 00144 | USRE47437, Example ({3-...)
Affinity DataIC50: 2.60E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107695(US8722895, 1: {[5-(3-chloro-phenyl)-3-hydroxy-pyri...)
Affinity DataIC50: 2.80E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107696(US8722895, 2: {[5-(4-Chloro-phenyl)-3-hydroxy-pyri...)
Affinity DataIC50: 3.70E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107700(US8722895, 6: [(3-Hydroxy-5-(4-methylphenyl)-pyrid...)
Affinity DataIC50: 4.10E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM301819(US9598370, Example 00143 | USRE47437, Example {[5-...)
Affinity DataIC50: 5.10E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM301787(US9598370, Example 00128 | USRE47437, Example {[5-...)
Affinity DataIC50: 5.80E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107701(US8722895, 7: {[5-(2-Chloro-phenyl)-3-hydroxy-pyri...)
Affinity DataIC50: 6.80E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107719(US8722895, 25: ({5-[3-(cyclopropanecarbonyl-amino)...)
Affinity DataIC50: 9.20E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107715(US8722895, 21: {[5-(3-Carbamoyl-phenyl)-3-hydroxy-...)
Affinity DataIC50: 1.12E+4nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

Displayed 1 to 50 (of 55 total ) | Next | Last >>
Jump to: